Background at the 2 listed urls:
http://www.diagnosticimaging.com/display/article/113619/1191417
http://stroke.ahajournals.org/content/32/11/2709.full
Treated patients enjoyed a near-total resolution of deficit more often (30% to 50% relative benefit) compared with placebo.
His stroke attacked the brain stem, the one section of the brain that is essentially immune to this drug’s effect.
from Elkhart General Hospital notes.
tPA is not useable in the 15% of cases that are hemorrhagic or the 14% of cases that occur while sleeping. With this poor usability why are we continuing to push this as the only hyperacute therapy?
Even though stroke is the third leading cause of death in the United States, there is only one approved treatment. Furthermore, fewer than 5% of stroke patients benefit from this treatment. New therapeutic targets are therefore urgently needed. Only 2% of stroke patients at 15 Michigan hospitals received the clot-busting treatment
Following statistics come from stroke presentations on www.slideshare.net
In the 3 hour window, of every 100 treated with tPA 32 benefit 3 are harmed - stroke 2007: 38:2279-2283
In the 3-4.5 hour window of every 100 treated with tPA 16 benefit 3 are harmed
With such dismal statistics where is the outcry to find something better or in addition. Hyperacute research needed.
No comments:
Post a Comment